CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment
Citing pipeline advancements and possible catalysts, Evercore ISI analyst Liisa Bayko raised CRISpen Therapeutics from "In Line" to "Outperform." The company focused on the CTX320 and CTX310 in vivo gene editing initiatives, giving respectively 10% and 5% success rates. Second quarter of 2025 data from CTX320 is anticipated to line up with Novartis's cardiovascular outcomes study. Mid-2025 should provide updates on CTX112 (CAR-T treatment), CTX131 (oncology), and CTX221 (type 1 diabetes).
Warning! GuruFocus has detected 4 Warning Signs with CRSP.
From $1.7 billion at the end of 2023, the corporation said in December 31, 2024, $1.9 billion in cash, cash equivalents, and marketable securities. Compared with 40 at the end of October, the Casgevy cell collection program also grew with over 50 fresh collections in the last nine weeks of the fourth quarter.
Although the firm's risk-adjusted model puts in low success probability for its new in vivo activities, its financial situation and clinical advancements indicate a better picture.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 minutes ago
- Business Wire
Labaton Keller Sucharow LLP Files Securities Class Action Against Fiserv, Inc. and Certain of Its Executives
NEW YORK--(BUSINESS WIRE)--Labaton Keller Sucharow LLP ('Labaton') has filed a securities class action lawsuit (the 'Action') on behalf of its client the City of Hollywood Police Officers' Retirement System ('Hollywood Police') against Fiserv, Inc. ('Fiserv' or the 'Company') (NYSE: FI) and certain of its executives (collectively, 'Defendants'). The Action, which is captioned City of Hollywood Police Officers' Retirement System v. Fiserv, Inc., No. 25-cv- 06094 (S.D.N.Y.), asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder on behalf of all persons and entities that purchased or otherwise acquired Fiserv common stock between July 24, 2024 and July 22, 2025, inclusive (the 'Class Period'). Fiserv is a global provider of transaction processing software for banks and retail merchants. Fiserv's flagship product and most important growth driver is Clover, which provides merchants with a payment 'gateway' to facilitate the secure processing of credit, debit, and mobile payment transactions on behalf of financial institutions and their customers. The Action alleges that, throughout the Class Period, Defendants misled investors by failing to disclose that: (a) due to cost issues and other problems with its older Payeezy platform, Fiserv forced Payeezy merchants to migrate to its Clover platform; (b) Clover's revenue growth and gross payment volume ('GPV'), the total monetary value of transactions processed through Clover, were temporarily and unsustainably boosted by these forced conversions, which concealed a slowdown in new merchant business; (c) shortly after these conversions, a significant portion of former Payeezy merchants switched to competing solutions due to Clover's high pricing, significant down time, and systematic compatibility issues; (d) as a result of these merchant losses, Clover's GPV growth was significantly slowing, and its revenue growth was unsustainable; and (e) based on the foregoing, Fiserv's positive Class Period statements about Clover's growth strategies, competition, attrition, GPV growth, and business prospects were materially false and misleading. The market began to learn the truth about Defendants' fraud on April 24, 2025. On that date, Fiserv shocked investors by reporting Clover GPV growth of only 8 percent for the first quarter of 2025, a material stepdown from 2024 GPV rates of between 14 and 17 percent. The Company attributed this slowing growth to lower 2025 transaction volumes from Payeezy merchants who had converted to Clover. On this news, Fiserv stock dropped 18.5 percent, closing at $176.90 per share on April 24, 2025. Then, on May 15, 2025, Fiserv disappointed investors by disclosing that GPV growth deceleration would continue throughout 2025. On this news, Fiserv stock dropped 16.2 percent, closing at $159.13 per share on May 15, 2025. Finally, on July 23, 2025, Fiserv lowered the top end of its full-year organic growth guidance range and confirmed that its quarterly organic revenue in the Merchant segment had decelerated to 9 percent year-over-year from 11 percent in the previous quarter. On this news, Fiserv stock dropped 13.9 percent, closing at $143.00 per share on July 23, 2025. If you purchased or acquired Fiserv common stock during the Class Period and were damaged thereby, you are a member of the 'Class' and may be able to seek appointment as Lead Plaintiff. Lead Plaintiff motion papers must be filed no later than September 22, 2025. The Lead Plaintiff is a court-appointed representative for absent members of the Class. You do not need to seek appointment as Lead Plaintiff to share in any Class recovery in this action. If you are a Class member and there is a recovery for the Class, you can share in that recovery as an absent Class member. You may retain counsel of your choice to represent you in this action. If you would like to consider serving as Lead Plaintiff or have any questions about this lawsuit, you may contact Connor C. Boehme, Esq. of Labaton at (212) 907-0780, or via email at cboehme@ You can view a copy of the Complaint online here. Hollywood Police is represented by Labaton, which represents many of the largest pension funds in the United States and internationally with combined assets under management of more than $4.5 trillion. Labaton's litigation reputation is built on its half-century of securities litigation experience, more than ninety full-time attorneys, and in-house team of investigators, financial analysts, and forensic accountants. Labaton has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, Delaware, London, and Washington, D.C. More information about Labaton is available at
Axios
an hour ago
- Axios
OpenAI GPT-5 is coming early next month
OpenAI is expected to release its next big model — GPT-5 — in August, Axios has learned. Why it matters: The race to create the biggest and best AI models is accelerating as the Trump administration has said the U.S. must do " whatever it takes" to beat China. The big picture: GPT-5 was expected earlier, but OpenAI's release plan has shifted several times. CEO Sam Altman posted on X on July 19 that GPT-5 would be released "soon." Then Altman appeared July 23 on Theo Von's podcast, where he praised the abilities of the new model. GPT-5 use is already cropping up in the wild, as testers get their hands on the code and security experts do their red teaming — additional signs that the model is getting close to release. Between the lines: In addition to being better at coding and more powerful overall, GPT-5 is expected to combine the attributes of both traditional models and so-called reasoning models such as o3. Altman clarified that the model OpenAI recently used to achieve gold medal performance at the recent International Mathematical Olympiad would not be included in GPT-5. OpenAI is planning to launch GPT-5 with mini and nano versions that will also be available through its API, according to The Verge, which first reported the new timeline. The intrigue: OpenAI's new open weight model is also coming soon, but could arrive before or after GPT-5 depending on last minute schedule tweaks, Axios has heard.
Hamilton Spectator
an hour ago
- Hamilton Spectator
EB5 Capital Celebrates the Closing of Atlanta Woodrow Apartments (JF41)
WASHINGTON, July 24, 2025 (GLOBE NEWSWIRE) — EB5 Capital is pleased to announce the closing of its $42.4 million investment in Woodfield Development's Atlanta Woodrow Apartments (JF41) project. Located in Atlanta, Georgia, the high-unemployment Target Employment Area (TEA) project is a Class A multifamily development featuring 300 units across four modern apartment buildings and 25 townhomes. The development will include expansive amenity space, including a resort-caliber pool and lounge, commercial-quality fitness center, and vibrant gaming courtyard, all complemented by top-of-market interiors and finishes. Considered a significant tech hub and corporate city, Atlanta is home to many major companies including UPS, Coca-Cola, Delta Airlines, Home Depot, and CNN. JF41 is situated in the South Atlanta submarket, a rapidly developing area near downtown. The location offers convenient access to several major transportation routes and is only ten miles from Hartsfield-Jackson Atlanta International Airport, the world's busiest airport. 'This project is a great example of how the EB-5 Program helps redevelop communities,' said Jonathan Mullen, EB5 Capital's Senior Vice President of Investments. 'We're proud to be part of a project that will bring over 900 new jobs to a high-unemployment area and contribute to the continued growth of the South Atlanta region.' JF41 marks EB5 Capital's 21st multifamily investment and second project in the state of Georgia. Construction is expected to start in Q3 2025 and reach completion in Q1 2027. About EB5 Capital EB5 Capital provides qualified foreign investors opportunities to invest in job-creating commercial real estate projects under the United States Immigrant Investor Program (EB-5 Visa Program). As one of the country's oldest and most active Regional Center operators, the firm has raised more than one billion dollars of foreign capital across over 45 EB-5 projects. Headquartered in Washington, DC, EB5 Capital's distinguished track record and leadership in the industry has attracted investors from over 75 countries. Please visit for more information. Contact: Katherine Willis Director, Marketing & Communications media@
